secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001193125-25-125866
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO
-----------------------------------------------------------------------

- Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.
- Kaplan receives severance: 3 months base salary ($128,749.99) plus COBRA for 3 months.
- CEO Aoife Brennan appointed interim principal financial officer, effective May 24, 2025, retaining CEO role.
- No changes to Brennan's compensation or arrangements in connection with this appointment.
- Kaplan reaffirms confidentiality, non-compete (amended to exclude CD19/APRIL drugs), and non-solicitation obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/0001193125-25-125866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/d854335d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-125866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer